US adds biotech to China investment ban, but leaves drug licensing open

On Monday, we wrote about the US Treasury's draft outbound investment rules under the COINS Act, focusing on the expanded AI controls. But there's more to it: The draft rules would also bar US investment in Chinese biotech. Treasury calls the sector "an acute risk" to US national security, citing b...

NewsBeagle is a discovery engine. We show the headline, a short source-supplied summary and clear attribution. The complete reporting remains with the publisher.